1Jordana P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci, 2000,57 ( 8-9 ) : 1229- 1235.
2Markman M. New, expanded, and modified use of approved antineoplastic agents in ovarian cancer. Oncologist,2007,12 (2) : 186-190.
3Zorat PL, Paccagnella A, Cavaniglia G, et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst, 2004,96 ( 22 ) : 1714- 1717.
4Strumberg D, Brtigge S, Korn MW,et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non- seminomatous testicular cancer. Ann Oncol, 2002,13(2):229-236.
5Gholam D, Fizazi K, Terrier-Lacombe MJ, et al. Advanced seminoma-treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients. Cancer, 2003,98(4) :745-752.
6Wakelee H, Belani CP. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist,2005 ,Suppl(3) :1-10.
7Abratt RP, Hart GJ. 10-year update on chemotherapy for non- small cell lung cancer. Ann Oneol, 2006, Suppl(5 ) :v33-v36.
